The complaint filed by Schall, Brown & Schwartz LLP claims Ardelyx obscured significant obstacles affecting its core products, XPHOZAH and IBSRELA. According to the filing, the company faced mounting reimbursement barriers and stringent prior authorization requirements that hampered new-patient starts and prescription fulfillment. These operational hurdles reportedly undermined the company's public financial health statements, causing market losses when the true extent of the commercial strain became public.

While the class has not yet received formal certification, shareholders who suffered losses during the specified period may participate in the recovery process. Brian Schall and David Schwartz are overseeing the outreach from their Los Angeles office, offering consultations regarding potential claims. Investors are not required to act as lead plaintiffs to remain part of the class, though those who choose to take no action will remain absent members until the court grants certification.